Barinthus Biotherapeutics (BRNS) Capital Expenditures (2020 - 2025)
Barinthus Biotherapeutics' (BRNS) quarterly Capital Expenditures came in at $32000.0 in Q2 2025, down 83.33% YoY from $192000.0 in Q2 2024, and up 540.0% on a QoQ basis from $5000.0 in Q1 2025.
Barinthus Biotherapeutics (BRNS) Capital Expenditures (2020 - 2025) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Capital Expenditures data on file, last reported at $32000.0 in Q2 2025.
- Quarterly Capital Expenditures fell 83.33% year-over-year to $32000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 94.57% YoY) and the FY2025 annual result came in at $37000.0, down 95.85% from the prior year.
- Capital Expenditures advanced to $32000.0 in Q2 2025, from $5000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $5.1 million in Q3 2023 to a low of -$5.5 million in Q4 2023.
- A 5-year average of $151166.7 and a median of $293000.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures soared 2273.33% — and 2022, when it tumbled 1277.59%.
- Tracing BRNS's Capital Expenditures over 5 years: stood at $424000.0 in 2021, then plunged by 1277.59% to -$5.0 million in 2022, then slipped by 9.73% to -$5.5 million in 2023, then soared by 105.07% to $278000.0 in 2024, then plunged by 88.49% to $32000.0 in 2025.
- The last three Capital Expenditures figures came in at $32000.0 (Q2 2025), $5000.0 (Q1 2025), and $278000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Jun 30, 2024 | 192,000.00 |
| Jun 30, 2024 | 192,000.00 |
| Mar 31, 2024 | 308,000.00 |
| Mar 31, 2024 | 308,000.00 |
| Dec 31, 2023 | -5.48 Mn |
| Dec 31, 2023 | -5.48 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | 2.51 Mn |
| Mar 31, 2023 | 2.51 Mn |